MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Motor control"

  • 2019 International Congress

    Utility of a smartphone app in discretely assessing and monitoring symptoms of Parkinson’s disease

    N. Shaafi Kabiri, A. Best, S. Johnson, B. Ho, G. Eden, B. Dupee, M. Fedorovsky, J. Severson, D. Amato, B. Severson, J. Bhangu, J. Cosman, M. Erb, K. Thomas (Boston, MA, USA)

    Objective: To assess the utility of a cognitive and motor battery on a smartphone/smart watch combination in an at-home setting for remote assessment of PD…
  • 2019 International Congress

    Long-Term Treatment With Deutetrabenazine Is Associated With Continued Improvement in Tardive Dyskinesia: Results From an Open-Label Extension Study

    R. Hauser, H. Barkay, H. Fernandez, S. Factor, J. Jimenez-Shahed, N. Gross, M. Gordon, JM. Savola, K. Anderson (Tampa, FL, USA)

    Objective: To evaluate long-term efficacy of deutetrabenazine in patients with tardive dyskinesia (TD) by examining the change from baseline in Abnormal Involuntary Movement Scale (AIMS)…
  • 2018 International Congress

    Swimming in PD patients with STN-DBS: A pilot exploratory study

    D. Flisar, S. Ibrulj, M. Trošt, M. Benedičič, P. Mušič, S. Korelc, K. Groleger Sršen (Ljubljana, Slovenia)

    Objective: Patients with PD frequently complain of losing abilitiy to swim. Our aim was to test the swimming abilities of our patients with bilateral STN-DBS…
  • 2018 International Congress

    Does the Parkinson’s Kinetigraph change clinical practice?

    S. Jones, C. Grose, S. Mahon, T. Williams, C. Thomas, B. Mohamed (Cardiff, United Kingdom)

    Objective: To assess whether information obtained from Parkinson’s Kinetigraph (PKG) influences clinical decision-making. Background: PKG is a relatively new technology: the device is worn continuously…
  • 2018 International Congress

    Motivational effects on action selection and memory

    S. Hirschbichler, J. Ibáñez, L. Rocchi, R. Greenwood, J. Rothwell, S. Manohar (London, United Kingdom)

    Objective: Eye movements provide important insights into the pathophysiology of neurological disorders. Here two paradigms were devised to quantify effects of motivation on motor control…
  • 2018 International Congress

    Dissociative effects of thyrotropin releasing hormone on classical cerebellar ataxic signs and cerebellar adaptation in patients with spinocerebellar degeneration

    T. Shimizu, R. Hanajima, R. Tsutsumi, N. Tominaga, Y. Ugawa, K. Nishiyama (Sagamihara, Japan)

    Objective: To reveal effects of TRH [Thyrotropin releasing hormone (protirelin tartrate)] on the prism adaptation task in patients with spinocerebellar degeneration (SCD). Background: The cerebellum…
  • 2018 International Congress

    Pilot economic evaluation of Personal KinetiGraph (PKG) for management of Parkinson’s disease in Australia

    P. Lynch, D. Jackson, D. Tilden, M. Horne (Minnetonka, MN, USA)

    Objective: To determine the potential cost savings and quality of life gains with the Personal KinetiGraph (PKG) in the management of patients with Parkinson’s disease…
  • 2018 International Congress

    Influence of dopamine deficiency on interhemispheric crosstalk in Parkinson’s disease

    P. Loehrer, F. Nettersheim, I. Weber, F. Jung, L. Timmermann (Marburg, Germany)

    Objective: To identify the significance of dopaminergic depletion in Parkinson’s disease (PD) on interhemispheric crosstalk using a complex bimanual tapping task. Background: Dopamine deficiency in…
  • 2018 International Congress

    A randomized, double-blind, placebo-controlled Phase II Efficacy and Safety Study of the PDE10A inhibitor PF-02545920 in Huntington Disease (AMARYLLIS)

    M. Delnomdedieu, Y. Tan, A. Ogde, Z. Berger, R. Reilmann (Cambridge, MA, USA)

    Objective: To assess efficacy on motor function, safety and tolerability of the phosphodiesterase-10A inhibitor PF-02545920 in Huntington disease (HD). Conclusion: PF-02545920 was generally safe and…
  • 2018 International Congress

    Costs and outcomes for Parkinson’s disease patients who have their management adjusted by Personal KinetiGraph (PKG)

    P. Lynch, D. Jackson, D. Tilden, M. Horne (Minnetonka, MN, USA)

    Objective: To quantify the potential cost savings and quality adjusted life years (QALYs) gained for people with Parkinson’s disease in Australia whose oral therapy was…
  • « Previous Page
  • 1
  • …
  • 15
  • 16
  • 17
  • 18
  • 19
  • …
  • 36
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • #25062 (not found)
    • Welcome to the MDS Abstracts Site
    • Effect of marijuana on Essential Tremor: A case report
    • Advanced Search
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley